Analysts at B.Riley FBR Didn’t Change their “Buy” rating for Miragen Therapeutics (MGEN). The Price Target is Set to $18.5000; Dana Holding (DAN) Sentiment Is 1.43

B.Riley FBR currently has a $18.5000 target price on the $232.18M market cap company or 140.57% upside potential. In a report sent to clients and investors on 10 May, Miragen Therapeutics Inc (MGEN) stock had its “Buy” Rating maintained by research professionals at B.Riley FBR.

Dana Holding Corp (DAN) investors sentiment increased to 1.43 in Q4 2017. It’s up 0.40, from 1.03 in 2017Q3. The ratio has improved, as 136 hedge funds increased or started new equity positions, while 95 trimmed and sold holdings in Dana Holding Corp. The hedge funds in our database now have: 137.75 million shares, down from 137.76 million shares in 2017Q3. Also, the number of hedge funds holding Dana Holding Corp in top ten equity positions was flat from 3 to 3 for the same number . Sold All: 16 Reduced: 79 Increased: 80 New Position: 56.

The stock increased 2.40% or $0.18 during the last trading session, reaching $7.69. About 136,594 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 43.43% since May 14, 2017 and is downtrending. It has underperformed by 54.98% the S&P500.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Seekingalpha.com which released: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018, also Nasdaq.com with their article: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 09, 2018, Streetinsider.com published: “miRagen Therapeutics (MGEN) to Highlight New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis …” on May 09, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Nasdaq.com and their article: “miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018” published on May 02, 2018 as well as Streetinsider.com‘s news article titled: “miRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound …” with publication date: April 27, 2018.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $232.18 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The company??s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

Among 9 analysts covering Miragen Therapeutics (MGEN), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $1300 lowest target. $16’s average target is 108.06% above currents $7.69 stock price. Miragen Therapeutics had 21 analyst reports since February 21, 2017 according to SRatingsIntel. The company was maintained on Tuesday, March 27 by FBR Capital. The rating was maintained by Chardan Capital Markets with “Buy” on Monday, August 14. The firm earned “Buy” rating on Friday, December 1 by Wedbush. The firm has “Outperform” rating by Wedbush given on Tuesday, February 21. The rating was maintained by Wedbush on Monday, April 30 with “Buy”. Wedbush initiated it with “Buy” rating and $1900 target in Wednesday, March 28 report. As per Tuesday, March 27, the company rating was initiated by Oppenheimer. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Friday, February 2 by FBR Capital. On Monday, October 16 the stock rating was maintained by Wedbush with “Buy”. The company was initiated on Thursday, January 11 by Oppenheimer.

Since January 1, 0001, it had 0 buys, and 4 sales for $3.39 million activity.

The stock decreased 1.42% or $0.34 during the last trading session, reaching $23.65. About 738,562 shares traded. Dana Incorporated (DAN) has risen 38.03% since May 14, 2017 and is uptrending. It has outperformed by 26.48% the S&P500.

Weber Alan W holds 7.3% of its portfolio in Dana Incorporated for 520,993 shares. Anchor Bolt Capital Lp owns 2.19 million shares or 2.54% of their US portfolio. Moreover, Origin Asset Management Llp has 1.63% invested in the company for 886,816 shares. The North Carolina-based Wedge Capital Management L L P Nc has invested 1.61% in the stock. Adirondack Research & Management Inc., a New York-based fund reported 90,704 shares.

Ratings analysis reveals 67% of Dana Inc’s analysts are positive. Out of 3 Wall Street analysts rating Dana Inc, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $17.0 while the high is $24.0. The stock’s average target of $20.33 is -14.04% below today’s ($23.65) share price. DAN was included in 3 notes of analysts from November 10, 2016. The firm has “Outperform” rating given on Tuesday, December 20 by RBC Capital Markets. On Thursday, November 10 the stock rating was downgraded by FBR Capital to “Mkt Perform”. The firm has “Buy” rating by Deutsche Bank given on Thursday, December 1.

Dana Incorporated (NYSE:DAN) Institutional Positions Chart